FDA Regulation of AI in Drug Manufacturing & QC

Last updated: 2026-03-30

Artificial intelligence is no longer a future-state concept in pharmaceutical manufacturing — it is actively running process analytical technology (PAT) systems, predicting equipment failures, flagging out-of-specification results, and informing real-time release testing decisions in facilities around the world. The question manufacturers are asking in 2025 and 2026 is not whether to adopt AI, but how to do it in a way that satisfies FDA's evolving expectations.

As someone who has guided 200+ clients through FDA audits and compliance programs at Certify Consulting, I can tell you that the regulatory landscape around AI in drug manufacturing is moving faster than most quality teams realize — and that first-mover advantage goes to companies that build compliant AI frameworks now, before enforcement catches up.

This pillar article covers the full picture: FDA's current regulatory authority, the key guidance documents you need to know, what GMP compliance looks like in an AI-enabled environment, and the practical steps your quality team should take today.

Why AI in Drug Manufacturing Is a Regulatory Priority Right Now

The momentum is unmistakable. According to FDA's own reporting, the agency received over 500 AI/ML-enabled drug application submissions between 2016 and 2023, with the rate of submissions accelerating sharply after 2020. Industry analysts at McKinsey & Company project that AI-enabled manufacturing processes could reduce pharmaceutical production costs by 20–30% while simultaneously improving yield consistency — numbers that make regulatory friction worth navigating.

FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have both flagged AI in manufacturing as a strategic priority under the agency's broader Advanced Manufacturing initiative. This is not incidental. FDA sees AI as central to its goal of modernizing pharmaceutical manufacturing under the framework established by the 21st Century Cures Act and subsequent reauthorizations.

The agency published its "Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products" discussion paper in 2023, signaling that formal guidance was coming. That signal has since been followed by additional draft guidance, workshop transcripts, and CDER Data Standards updates that together form a working regulatory framework — even if that framework is not yet fully codified.

Citation hook: FDA's 2023 AI/ML discussion paper established that AI systems used in drug manufacturing are subject to existing GMP regulations under 21 CFR Parts 210 and 211, with no separate AI-specific GMP framework currently in effect.

FDA's Existing Regulatory Authority Over AI in Manufacturing

21 CFR Parts 210 and 211: The GMP Foundation

The foundational answer to "how does FDA regulate AI in drug manufacturing" is straightforward: through existing Current Good Manufacturing Practice (cGMP) regulations. AI systems do not exist in a regulatory vacuum. When an AI model is used to monitor a bioreactor, adjust process parameters, or make a batch disposition recommendation, it is functioning as part of the manufacturing process and is therefore subject to cGMP requirements.

Key regulatory touchpoints under 21 CFR Part 211 include:

211.68 — Automatic, mechanical, and electronic equipment must be routinely calibrated, inspected, and checked according to a written program. AI systems used in manufacturing fit squarely within this provision.
211.100 — Written procedures for production and process controls must be followed. If an AI system is executing or informing those controls, the procedures must account for AI decision logic.
211.192 — All production and process control records must be reviewed. This extends to logs and audit trails generated by AI systems.
211.22 — Quality control unit responsibilities cannot be fully delegated to an AI system without human oversight — a point FDA has reinforced explicitly in guidance language.

21 CFR Part 11: Electronic Records and AI Audit Trails

AI systems generate electronic records and, in some cases, electronic signatures. Part 11 compliance is therefore directly implicated. Audit trails for AI-driven decisions — including inputs, model version, outputs, and any overrides — must meet Part 11 requirements for accuracy, completeness, and integrity. This is an area where many manufacturers underinvest, and it is increasingly a focus of FDA Form 483 observations.

FDA's Process Analytical Technology (PAT) Framework

Published in 2004 but still the primary framework for real-time manufacturing controls, FDA's PAT guidance provides the closest analog to a formal AI-in-manufacturing framework. AI systems that function as PAT tools — using spectroscopic data, process signals, or sensor feeds to make real-time decisions — should be validated and documented under PAT principles, including design of experiments, chemometric model validation, and continuous monitoring protocols.

Key FDA Guidance Documents Governing AI in Drug Manufacturing

The table below summarizes the most important FDA guidance and policy documents relevant to AI in pharmaceutical manufacturing and quality control as of early 2026:

| Document | Year | Scope | Key Requirement for AI || |---|---|---|---| | 21 CFR Parts 210/211 (cGMP) | Ongoing | All drug manufacturing | AI systems subject to equipment qualification, procedure requirements, QC oversight | | 21 CFR Part 11 | 1997/Updated | Electronic records | Audit trails, access controls, record integrity for AI outputs | | FDA PAT Guidance | 2004 | Real-time manufacturing controls | Model validation, risk-based deployment, continuous monitoring | | FDA AI/ML Discussion Paper | 2023 | Drug & biologic product development | Signals intent; establishes AI is subject to existing frameworks | | FDA Draft Guidance: Computer Software Assurance (CSA) | 2022 | Software used in manufacturing | Risk-based validation replacing CSV; directly applies to AI software | | FDA Advanced Manufacturing Guidance | 2023 | Continuous manufacturing, AI/PAT | Encourages AI adoption; requires prior communications for novel implementations | | ICH Q9(R1) — Quality Risk Management | 2023 | All GMP operations | AI model risk assessment must follow formal QRM methodology | | ICH Q10 — Pharmaceutical Quality System | 2008/Ongoing | Quality management systems | AI governance embedded in PQS; CAPA for AI model drift |

Computer Software Assurance: The Validation Framework That Changes Everything

Perhaps the single most important development for AI in manufacturing compliance is FDA's 2022 draft guidance on Computer Software Assurance (CSA), which replaces the outdated Computer System Validation (CSV) framework for GMP software.

CSA is explicitly risk-based. Rather than generating mountains of IQ/OQ/PQ documentation for every software system regardless of impact, CSA directs manufacturers to scale assurance activities to the risk that a software failure would pose to product quality and patient safety. For AI systems, this means:

Intended use classification — What decisions is the AI making, and what is the consequence of an incorrect decision?
Risk-proportionate testing — High-risk AI applications (e.g., real-time release decisions) require more rigorous assurance than low-risk applications (e.g., predictive maintenance scheduling).
Objective evidence over documentation volume — FDA wants evidence that the system works correctly, not a documentation exercise.

Citation hook: Under FDA's Computer Software Assurance framework, AI systems used in drug manufacturing must be validated with a level of rigor proportionate to their intended use and the risk they pose to product quality — a departure from the one-size-fits-all CSV approach that previously governed GMP software.

For quality teams managing AI deployments, CSA is a relief and a responsibility. The relief: you don't need 500-page validation protocols for a predictive maintenance tool. The responsibility: you need a defensible risk classification process, and FDA will scrutinize your methodology.

What FDA Inspectors Are Looking for in AI-Enabled Facilities

Based on publicly available FDA Warning Letters, 483 observations, and my direct experience supporting clients through pre-approval inspections and surveillance audits, FDA investigators are focusing on several specific areas when they encounter AI in manufacturing environments:

1. Model Validation and Revalidation

Investigators want to see documented evidence that AI models were validated before deployment and that there is an ongoing program to detect and respond to model drift. A model trained on 2022 process data that has never been revalidated is a significant observation risk — particularly if the manufacturing process, raw material suppliers, or equipment have changed.

2. Human Oversight and Override Procedures

FDA has been consistent: AI cannot replace the qualified human judgment required by cGMP. Investigators will ask to see written procedures for how operators interact with AI systems, how they override AI recommendations, and how those overrides are documented and reviewed as potential signals.

3. Change Control for AI Models

When an AI model is updated — whether through retraining, hyperparameter adjustment, or vendor update — that change must go through a formal change control process under 21 CFR 211.100 and your site's quality system. Many companies are discovering that their change control SOPs were written for physical equipment and reagents, not software models. FDA inspectors are catching this gap.

4. Data Integrity for AI Inputs and Outputs

AI systems are only as reliable as the data they consume. FDA investigators are examining data governance practices around AI: Is the training data documented and traceable? Are input sensors calibrated? Are AI outputs stored with sufficient metadata to reconstruct the decision context? ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, Available) apply to AI-generated records.

5. Supplier Qualification for AI Vendors

If you are using a third-party AI platform or a contract AI development firm, FDA expects you to have qualified that supplier under your Quality Agreement framework. The fact that an AI vendor is not a traditional raw material supplier does not exempt them from your supplier qualification program.

Continuous Manufacturing and AI: A Special Case

FDA has been particularly enthusiastic about AI in the context of continuous manufacturing (CM), where real-time process control is not optional — it is the operational model. The agency's 2019 guidance on CM and subsequent Q&A documents make clear that AI-enabled control systems are a natural fit for CM environments, but they come with heightened expectations:

Established Conditions (ECs): Manufacturers must define which process parameters are Established Conditions requiring a prior approval supplement versus those that can be managed under the site's quality system. AI model architecture and decision boundaries may constitute ECs depending on their criticality.
Real-Time Release Testing (RTRT): AI models supporting RTRT decisions must meet a higher validation standard and are subject to prospective FDA review in many cases.
Control Strategy Documentation: The overall control strategy submitted in an NDA or ANDA must reflect how AI fits into the control architecture.

According to FDA's Center for Drug Evaluation and Research, as of 2024 there were more than 30 approved drug products manufactured using continuous manufacturing processes, many of which incorporate AI-enabled process control elements.

Building a Compliant AI Governance Framework for Drug Manufacturing

For manufacturers building or maturing their AI governance programs, I recommend structuring your framework around five pillars:

Pillar 1: AI Inventory and Risk Classification

Maintain a living inventory of every AI system touching manufacturing or quality decisions. Classify each by intended use, decision type (advisory vs. autonomous), and patient safety risk. This inventory becomes the basis for proportionate assurance activities.

Pillar 2: Lifecycle Validation Under CSA Principles

Deploy AI systems using a risk-based validation approach aligned with FDA's CSA framework. Document intended use, acceptance criteria, and testing evidence. Build revalidation triggers into your SOPs.

Pillar 3: Data Governance and Integrity Controls

Establish documented data governance policies covering AI training data, input data quality, and output record retention. Apply ALCOA+ to AI-generated records. Conduct periodic data integrity audits of AI system inputs and outputs.

Pillar 4: Change Control and Model Management

Expand your change control SOP to explicitly address AI model updates, vendor-initiated changes, retraining events, and architecture changes. Define thresholds that trigger formal change control versus routine model maintenance.

Pillar 5: Human Oversight and CAPA Integration

Define clear human oversight requirements for every AI application. Integrate AI performance monitoring into your CAPA system — model drift, unexpected outputs, and operator overrides should feed into your quality review process as potential signals.

Citation hook: A compliant AI governance framework for pharmaceutical manufacturing must address five core pillars: AI inventory and risk classification, lifecycle validation, data governance and integrity, change control for model updates, and structured human oversight integrated with the site's CAPA system.

What to Expect from FDA in 2025–2026

The regulatory environment is actively developing. Here is what manufacturers should watch:

Finalization of AI/ML guidance: FDA's 2023 discussion paper is expected to mature into formal draft guidance covering AI in drug development and manufacturing. Comments from the pharmaceutical industry have already shaped the agency's thinking.
International convergence: ICH is actively working on AI-specific annexes under the Q-series guidelines. Manufacturers operating globally should expect harmonized requirements that align with FDA's risk-based approach but may include additional transparency and explainability requirements.
Increased inspection focus: FDA has trained a cadre of investigators specifically in AI and data integrity assessment. Expect AI systems to receive direct scrutiny in both pre-approval inspections and surveillance audits.
Enforcement escalation: Early FDA enforcement around AI has been limited, but the agency has signaled that data integrity violations connected to AI systems will be treated with the same seriousness as traditional data integrity failures.

If your facility is in the early stages of AI adoption, now is the right time to build a compliant framework — before an inspector walks through your door. Explore our FDA compliance resources for drug manufacturers or learn more about how Certify Consulting approaches GMP quality system modernization for facilities implementing advanced manufacturing technologies.

Frequently Asked Questions

Q: Does FDA require a separate validation protocol for AI systems used in drug manufacturing? A: Not a separate framework, but AI systems must be validated. FDA's Computer Software Assurance (CSA) draft guidance provides the current framework, replacing traditional Computer System Validation (CSV) with a risk-based approach. The level of rigor required scales with the AI system's intended use and the risk it poses to product quality.

Q: Can an AI system make a final batch disposition decision without human review? A: No. Under 21 CFR 211.22, the quality control unit retains ultimate responsibility for batch disposition decisions. AI can support and inform that decision, but a qualified human must review and authorize the final disposition. Fully autonomous AI batch release is not compliant with current cGMP requirements.

Q: What happens when an AI model is updated or retrained — does it require a new validation? A: Yes, model updates must go through change control, and material changes to model architecture, training data, or decision thresholds typically require revalidation activities. The scope of revalidation should be proportionate to the nature and risk of the change, consistent with CSA principles.

Q: Are AI systems from third-party vendors subject to supplier qualification? A: Yes. AI software vendors providing tools used in GMP-regulated manufacturing operations must be qualified under your supplier qualification program and covered by a Quality Agreement that defines responsibilities for validation support, change notification, and data integrity.

Q: How should AI-generated records be managed for data integrity compliance? A: AI-generated records must meet ALCOA+ requirements and, if stored electronically, comply with 21 CFR Part 11. This includes maintaining audit trails for AI inputs, outputs, model version used, and any human overrides. Records must be complete, enduring, and retrievable for the duration required by cGMP.

Summary: The Regulatory Reality of AI in Drug Manufacturing

FDA's approach to AI in drug manufacturing is pragmatic and grounded in existing cGMP authority. The agency is not waiting for a dedicated AI statute — it is applying 21 CFR Parts 210, 211, Part 11, PAT guidance, and the CSA framework to AI systems right now, and its investigators are trained to examine these systems during inspections.

Manufacturers that treat AI as just another piece of GMP equipment — subject to qualification, validation, change control, and human oversight — will be well-positioned. Those that deploy AI without a structured governance framework are accumulating regulatory risk with every production batch.

At Certify Consulting, I work with manufacturers at every stage of AI maturity, from initial risk assessments to full AI governance program builds. With a 100% first-time audit pass rate across 200+ clients and eight-plus years of FDA compliance experience, we understand how to translate FDA's evolving expectations into practical, audit-ready programs.

Ready to assess your AI compliance posture? Visit certify.consulting to connect with our team.